Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Exclusion Criteria

• •Eligible for otherwise curative treatment or undergoing concurrent therapy
• •Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor
• •Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
• •Clinical ascites
• •Any single lesion greater than or equal to 4 cm (per RECIST v1.1)
• •Malignant bowel obstruction
• •History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes)
• •Recent history of thyroiditis
• •Presence of a serious acute infection or chronic infection
• •Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
• •GI condition that might limit absorption of oral agents
• •Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
• •Ongoing treatment with steroid therapy or other immunosuppressive
• •Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors
• •Receipt of live attenuated vaccines
• •Acute or chronic skin and/or microvascular disorders
• •Edema or lymphedema in the lower limbs \> grade 2